Stryker Still Rolling With The Punches

I believe there's a case to be made that Stryker (NYSE:SYK) is among the best-run med-tech companies in the last quarter-century, and maybe one of the best-run companies overall. Through multiple management transitions, numerous M&A transactions, and significant shifts in the med-tech landscape (in terms of technology, competition, reimbursement, etc.), this company has remained a surprisingly consistent grower and a good steward of capital.